The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Bioeng. Biotechnol.
Sec. Bioprocess Engineering
Volume 12 - 2024 |
doi: 10.3389/fbioe.2024.1459273
Automated CRISPR/Cas9-based genome editing of human pluripotent stem cells using the StemCellFactory
Provisionally accepted- 1 Fraunhofer Institute for Production Technology (FHG), Aachen, Germany
- 2 LIFE & BRAIN GmbH, Bonn, North Rhine-Westphalia, Germany
- 3 Institute of Reconstructive Neurobiology, University of Bonn, Bonn, North Rhine-Westphalia, Germany
- 4 Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
- 5 Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University, Aachen, North Rhine-Westphalia, Germany
- 6 Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany
- 7 Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany
- 8 Faculty of Medicine, University of Bonn, Bonn, Germany
- 9 Laboratory for Machine Tools and Production Engineering, RWTH Aachen University, Aachen, Germany
CRISPR-Cas9 genome editing is a rapidly advancing technology that has the potential to accelerate research and development in a variety of fields. However, manual genome editing processes suffer from limitations in scalability, efficiency, and standardization. The implementation of automated systems for genome editing addresses these challenges, allowing researchers to cover the increasing need and perform large-scale studies for disease modeling, drug development, and personalized medicine. In this study, we developed an automated CRISPR/Cas9-based genome editing process on the StemCellFactory platform. We implemented a 4D-Nucleofector with a 96-well shuttle device into the StemCellFactory, optimized several parameters for single cell culturing and established an automated workflow for CRISPR/Cas9-based genome editing. When validated with a variety of genetic backgrounds and target genes, the automated workflow showed genome editing efficiencies similar to manual methods, with indel rates of up to 98%. Monoclonal colony growth was achieved and monitored using the StemCellFactory-integrated CellCelector, which allowed the exclusion of colonies derived from multiple cells or growing too close to neighbouring colonies. In summary, we demonstrate the successful establishment of an automated CRISPR/Cas9-based genome editing process on the StemCellFactory platform. The development of such a standardized and scalable automated CRISPR-Cas9 system represents an exciting new tool in genome editing, enhancing our ability to address a wide range of scientific questions in disease modeling, drug development and personalized medicine.
Keywords: Genome editing, CRISPR/Cas9, Automation, StemCellFactory, Induced Pluripotent Stem Cells, iPS cells Running Title
Received: 03 Jul 2024; Accepted: 27 Aug 2024.
Copyright: © 2024 Nießing, Breitkreuz, Elanzew, De Toledo, Vajs, Nolden, Erkens, Wanek, Au Yeung, Haupt, König, Peitz, Schmitt, Zenke and Brüstle. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Bastian Nießing, Fraunhofer Institute for Production Technology (FHG), Aachen, Germany
Andreas Elanzew, Institute of Reconstructive Neurobiology, University of Bonn, Bonn, D-53127, North Rhine-Westphalia, Germany
Si Wah C. Au Yeung, Institute of Reconstructive Neurobiology, University of Bonn, Bonn, D-53127, North Rhine-Westphalia, Germany
Michael Peitz, LIFE & BRAIN GmbH, Bonn, 53127, North Rhine-Westphalia, Germany
Oliver Brüstle, LIFE & BRAIN GmbH, Bonn, 53127, North Rhine-Westphalia, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.